April 8, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company
developing drug candidates for the prevention and treatment of cancer, today announced that Helix’s
Chief Science Officer, Dr. Heman Chao, will be presenting a scientific poster at American Association
for Cancer Research (AACR) Annual Meeting in Washington, DC on Tuesday April 9, 2013.
Dr. Chao’s poster, entitled, Development of an alkalizing antibody-enzyme conjugate for NSCLC
treatment in Phase I clinical testing, highlights the pre-clinical development results of L-DOS47 and
describes the design of the Phase I/II clinical study ongoing in Poland. Dr. Chao will be available at
AACR on Tuesday April 9th, 2013 to discuss his presentation. A copy of the poster will be made
available on Helix’s website for viewing at www.helixbiopharma.com on April 9, 2013.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The
company is actively developing innovative products for the prevention and treatment of cancer based on
its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the
Helix BioPharma Corp.
Tel: 905 841-2300
This news release contains certain forward-looking statements and information (collectively, “forwardlooking statements”) within the meaning of applicable Canadian securities laws, including, without
limitation, those relating to the potential benefits of Helix’s DOS47 platform in the treatment of cancer.
Forward-looking statements, which may be identified by words including, without limitation, “will” and
other similar expressions, are intended to provide information about management’s current plans and
expectations regarding future operations.
Although Helix believes that the expectations reflected in such forward-looking statements are
reasonable, such statements involve risks and uncertainties that may cause actual results or events to
differ materially from those anticipated and no assurance can be given that these expectations will be
realized, and undue reliance should not be placed on such statements. Risk factors that could cause
actual results or events to differ materially from the forward-looking statements include, without
limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully; (iii) need to secure additional
financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results
that do not justify future clinical development, including that the Polish Phase I/II clinical trial for LDOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more
fully described in Helix’s most recent Annual Information Form, including under the headings “ForwardLooking Statements” and “Risk Factors”, filed with the Canadian Securities Administrators at
www.sedar.com (together, the “Helix Risk Factors”). Certain material factors or assumptions are applied
in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will
not cause Helix’s actual results or events to differ materially from the forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions and expectations of
Helix’s management on the date of this news release, and Helix does not assume any obligation to
update any forward-looking statement or information should those beliefs, assumptions or expectations,
or other circumstances change, except as required by law.